دورية أكاديمية
أعرض في EDS

Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis.

التفاصيل البيبلوغرافية
العنوان: Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis.
المؤلفون: Liu X; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Xi R; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Du X; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Wang Y; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Cheng L; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Yan G; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Lu H; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Liu T; Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China., Li F; Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2024 Jul 04; Vol. 18, pp. 2775-2791. Date of Electronic Publication: 2024 Jul 04 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Auckland, N.Z.] : Dove Press Limited
مواضيع طبية MeSH: Psoriasis*/drug therapy , Psoriasis*/chemically induced , Psoriasis*/immunology , Psoriasis*/pathology , Skin*/drug effects , Skin*/pathology , Imiquimod*/pharmacology , Thymopentin*/pharmacology, Animals ; Mice ; T-Lymphocyte Subsets/drug effects ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Disease Models, Animal ; Mice, Inbred BALB C ; Female ; Microbiota/drug effects ; Male ; Mice, Inbred C57BL
مستخلص: Background: Psoriasis is a common chronic inflammatory skin condition. The emergence of psoriasis has been linked to dysbiosis of the microbiota on the skin surface and an imbalance in the immunological microenvironment. In this study, we investigated the therapeutic impact of topical thymopentin (TP5) on imiquimod (IMQ)-induced psoriasis in mice, as well as the modulatory influence of TP5 on the skin immune milieu and the skin surface microbiota.
Methods: The IMQ-induced psoriasis-like lesion mouse model was used to identify the targets and molecular mechanisms of TP5. Immunofluorescence was employed to identify differences in T-cell subset expression before and after TP5 therapy. Changes in the expression of NF-κB signaling pathway components were assessed using Western blotting (WB). 16S rRNA sequencing and network pharmacology were used to detect changes in the skin flora before and after TP5 administration.
Results: In vivo, TP5 reduced IMQ-induced back inflammation in mice. H&E staining revealed decreased epidermal thickness and inflammatory cell infiltration with TP5. Masson staining revealed decreased epidermal and dermal collagen infiltration after TP5 administration. Immunohistochemistry showed that TP5 treatment dramatically reduced IL-17 expression. Results of the immunoinfiltration analyses showed psoriatic lesions with more T-cell subsets. According to the immunofluorescence results, TP5 dramatically declined the proportions of CD4 + , Th17, ROR + , and CD8 + T cells. WB revealed that TP5 reduced NF-κB pathway expression in skin tissues from IMQ-induced psoriasis model mice. 16S rRNA sequencing revealed a significant increase in Burkholderia and Pseudomonadaceae_Pseudomonas and a significant decrease in Staphylococcaceae_Staphylococcus, Aquabacterium, Herbaspirillum, and Balneimonas . Firmicutes dominated the skin microbial diversity after TP5 treatment, while Bacteroidetes, Verrucomicrobia, TM7, Proteobacteria, Actinobacteria, Acidobacteria, Gemmatimonadetes, and other species dominated in the IMQ group.
Conclusion: TP5 may treat psoriasis by modulating the epidermal flora, reducing NF-κB pathway expression, and influencing T-cell subsets.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
(© 2024 Liu et al.)
References: Br J Dermatol. 2013 Jul;169(1):47-52. (PMID: 23521130)
Asian Pac J Trop Med. 2016 Mar;9(3):293-7. (PMID: 26972405)
Front Immunol. 2021 Oct 18;12:764384. (PMID: 34733291)
Gut. 2020 Feb;69(2):264-273. (PMID: 31097538)
J Eur Acad Dermatol Venereol. 2021 May;35(5):1152-1160. (PMID: 33428282)
Br J Dermatol. 2018 May;178(5):1020-1027. (PMID: 29071712)
Arch Dis Child. 1992 Sep;67(9):1095-102. (PMID: 1329673)
Drug Des Devel Ther. 2019 Jul 23;13:2491-2502. (PMID: 31413544)
Int J Mol Sci. 2022 Oct 28;23(21):. (PMID: 36361857)
Microbiome. 2013 Dec 23;1(1):31. (PMID: 24451201)
Front Immunol. 2023 Aug 04;14:1191782. (PMID: 37600764)
Immunol Res. 1998;17(3):345-68. (PMID: 9638477)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Expert Opin Investig Drugs. 2023 Jan-Jun;32(6):537-552. (PMID: 37243611)
J Am Acad Dermatol. 2021 Feb;84(2):579-581. (PMID: 33339674)
Int J Biol Sci. 2020 Mar 5;16(9):1575-1585. (PMID: 32226303)
Sci Rep. 2021 May 28;11(1):11265. (PMID: 34050205)
Ther Clin Risk Manag. 2022 Mar 25;18:287-298. (PMID: 35386182)
Front Cell Infect Microbiol. 2019 Feb 04;9:7. (PMID: 30778377)
J Allergy Clin Immunol. 1990 May;85(5):927-33. (PMID: 2185294)
Immunity. 2013 Oct 17;39(4):782-95. (PMID: 24138885)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
PLoS Negl Trop Dis. 2016 Sep 23;10(9):e0005015. (PMID: 27661612)
Clin Exp Immunol. 2019 Dec;198(3):403-415. (PMID: 31407330)
Arch Dermatol Res. 2012 Jan;304(1):15-22. (PMID: 22065152)
Microbiome. 2018 Sep 5;6(1):154. (PMID: 30185226)
Sci Transl Med. 2018 Oct 17;10(463):. (PMID: 30333238)
J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1689-1690. (PMID: 37622225)
Int J Mol Sci. 2021 Apr 13;22(8):. (PMID: 33924414)
Front Immunol. 2021 Feb 05;11:618312. (PMID: 33613547)
J Integr Med. 2022 Jul;20(4):376-384. (PMID: 35491357)
Immunity. 2019 Mar 19;50(3):552-565. (PMID: 30893586)
BMJ. 2022 Jan 26;376:e066452. (PMID: 35082139)
Nat Rev Immunol. 2018 Aug;18(8):514-525. (PMID: 29717233)
J Cosmet Dermatol. 2021 Apr;20(4):1066-1072. (PMID: 32998180)
Cell Host Microbe. 2016 Nov 9;20(5):596-605. (PMID: 27923703)
Nat Commun. 2018 Jun 8;9(1):2223. (PMID: 29884801)
Genome Biol. 2017 Nov 15;18(1):220. (PMID: 29141660)
Exp Dermatol. 2019 Feb;28(2):136-141. (PMID: 30506967)
Sci Immunol. 2022 Nov 18;7(77):eabq3254. (PMID: 36367947)
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1937-1946. (PMID: 35608188)
Int J Mol Sci. 2019 Mar 23;20(6):. (PMID: 30909615)
Lancet. 1985 Apr 13;1(8433):832-6. (PMID: 2858708)
J Allergy Clin Immunol. 2014 Feb;133(2):429-38. (PMID: 24269258)
Front Immunol. 2019 Aug 06;10:1841. (PMID: 31447849)
فهرسة مساهمة: Keywords: 16S rRNA sequencing; T-cell subsets; psoriasis; thymopentin
المشرفين على المادة: P1QW714R7M (Imiquimod)
O3Y80ZF13F (Thymopentin)
تواريخ الأحداث: Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240711
رمز التحديث: 20240711
مُعرف محوري في PubMed: PMC11231030
DOI: 10.2147/DDDT.S448550
PMID: 38984208
قاعدة البيانات: MEDLINE
الوصف
تدمد:1177-8881
DOI:10.2147/DDDT.S448550